6-Methyl-1,2,3,4-tetrahydrophenanthridine | 1006707-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-Methyl-1,2,3,4-tetrahydrophenanthridine
• CAS: 1006707-76-1
• 化学式: C₁₄H₁₅N
• 分子量: 197.28
• InChiKey: ANKUOVRMSJISMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-(cyclohex-1-en-1-yl)acetamide 、 2-(三甲基硅)苯基三氟甲烷磺酸盐 在 四丁基二氟三苯硅酸铵 作用下， 以 四氢呋喃 为溶剂， 以67%的产率得到6-Methyl-1,2,3,4-tetrahydrophenanthridine
  参考文献：
  名称：

  通过 Aryne Annulation 正交合成二氢吲哚和异喹啉

  摘要：

  本报告中描述了两种利用芳炔反应性的独特方法的发展。N-氨基甲酰基官能化的烯胺衍生物与苄的反应提供取代的二氢吲哚。当相关的烯胺衍生物被修饰为酰胺时，就会发现正交反应性，这样异喹啉就可以作为与苄缩合的产物形成。后一种转化适用于鸦片生物碱罂粟碱的简明全合成。

  DOI：

  10.1021/ja0780582

文献信息

• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：Universal Display Corporation

  公开号：US20190319198A1

  公开（公告）日：2019-10-17

  An organic light emitting device (OLED) that includes an anode, a cathode, and an organic layer disposed between the anode and the cathode. The organic layer includes a metal compound that comprises a ligand L A of Formula I, wherein the dashed lines represent coordination to a metal M. The metal M is selected from the groups consisting of Os, Ru, Ir, Rh, Pt, Pd, and Cu, and the metal is further coordinated to one or more ligand(s) L B , wherein the ligand(s) L B can be the same or different if more than one ligand L B is present. Optionally one or two of the ligand(s) L B can independently link to the ligand L A through one of R 1 to R 5 . The invention is also directed to a consumer product that includes an OLED, and the OLED includes an organic layer that includes a metal compound that comprises a ligand L A of Formula I.

  一种有机发光器件（OLED），包括阳极、阴极和位于阳极和阴极之间的有机层。有机层包括一个包含配体LA的化合物，其中虚线代表与金属M的配位。金属M选自Os、Ru、Ir、Rh、Pt、Pd和Cu组，金属进一步与一个或多个配体LB配位，如果有多个配体LB，则这些配体LB可以相同或不同。可选地，一个或两个配体LB可以独立地通过R1至R5中的一个连接到配体LA。该发明还涉及一种包括OLED的消费产品，该OLED包括一个包含配体LA的化合物的有机层。
• Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040138214A1

  公开（公告）日：2004-07-15

  Disclosed are substituted xanthines of general formula 1 wherein R 1 to R 4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式1的取代黄嘌呤，其中R1至R4的定义如下，其互变异构体、立体异构体、混合物、前药及其盐具有有价值的药理学特性，特别是对二肽基肽酶-IV（DPP-IV）酶活性具有抑制作用。
• XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
  申请人：HIMMELSBACH Frank

  公开号：US20090093457A1

  公开（公告）日：2009-04-09

  Disclosed are substituted xanthines of general formula wherein R 1 to R 4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明公开了一种通式为的取代黄嘌呤，其中R1至R4的定义如下，其互变异构体、立体异构体、混合物、前药及其盐具有有价值的药理学特性，特别是对酶二肽基肽酶-IV（DPP-IV）的抑制作用。
• Pyrimidine derivatives
  申请人：Sato Michitaka

  公开号：US20070197551A1

  公开（公告）日：2007-08-23

  This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X 1 stands for hydrogen, lower alkyl, amino, etc., X 2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0-4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT 3 antagonistic agent which concurrently exhibits 5-HT 1A agonistic activity, or administering 5-HT 1A agonistic agent and 5-HT 3 antagonistic agent simultaneously, in sequence or at an interval.

  本发明提供了由下式表示的嘧啶衍生物，其中，环A代表碳环基团或杂环基团，X1代表氢、低碳基、氨基等，X2代表氢或低碳基，Y代表直接键或硫或氮，n代表0-4的整数，Ar代表以下式的基团，或其盐，同时表现出5-HT1A激动活性和5-HT3拮抗活性，并且对治疗诸如肠易激综合征等疾病有用。本发明进一步提供了一种IBS治疗方法，其特征在于在体内同时和协同地发挥5-HT1A激动活性和5-HT3拮抗活性，包括给予同时表现出5-HT1A激动活性和5-HT3拮抗活性的5-HT3拮抗剂，或同时给予5-HT1A激动剂和5-HT3拮抗剂，按顺序或间隔给予。
• PYRIMIDINE DERIVATIVE
  申请人：ASKA Pharmaceutical Co., Ltd.

  公开号：EP1724267B1

  公开（公告）日：2013-11-06